ORYZON Announces Publication of Paper in Cancer Cell establishing the relevance of ORY-1001 as an antileukemic differentiating drug

5 March 2018 MADRID, SPAIN and CAMBRIDGE MA. Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the publication by company scientists of a new paper in the March issue of Cancer Cell. The paper describes the development of ORY-1001, a highly selective KDM1A inhibitor with unrivalled in vivo potency. KDM1A (also known as LSD1) is a histone lysine demethylase, reported to be essential for leukemic stem cell maintenance. Click here to see the full Press Release

The release as fetched from its publisher. oryzon.com ↗